Log in to save to my catalogue

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a poole...

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a poole...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9174181

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

About this item

Full title

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

Publisher

London: Nature Publishing Group UK

Journal title

British journal of cancer, 2022-06, Vol.126 (12), p.1715-1724

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Background
Anthracycline/cyclophosphamide-taxane-containing chemotherapy (AC-T) is the standard of care in the adjuvant treatment of HER2-negative early breast cancer (EBC), but recent studies suggest omission of anthracyclines for reduced toxicity without compromising efficacy.
Methods
Based on individual patient data (
n
 = 5924) p...

Alternative Titles

Full title

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9174181

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9174181

Other Identifiers

ISSN

0007-0920,1532-1827

E-ISSN

1532-1827

DOI

10.1038/s41416-021-01690-6

How to access this item